Feasibility of Combined Genomics/Transcriptomics for Patients With Lymphoma

Conditions

Lymphoma

Brief summary

To learn more about the usefulness of molecular testing with the Molecular Functional (MF) Portrait (a commercial test conducted by the sponsor of this study, BostonGene) in guiding lymphoma care.

Detailed description

Primary Objective: • To determine the feasibility and turnaround of clinical WES and transcriptome sequencing Secondary Objectives: * To determine the frequency of actionable DNA and RNA alterations * To determine the concordance of DNA and RNA alterations * To determine the frequency of molecularly matched therapy * To determine the feasibility of identifying mechanism(s) of acquired resistance with genomic profiling * To determine the feasibility of molecularly matched therapy to acquired resistance alterations Exploratory Objectives: * To determine the feasibility of prioritizing targets with precision analytics * To determine clinical outcomes in patients receiving molecularly matched therapy * To determine the role of additional emerging diagnostic technologies

Dai Chihara, Kumudha Balakrishnan, Gita Masand, R. Andrew Harkins, Neha Akkad et al. (20 authors)

Blood Advances2026-07-24

10.1182/bloodadvances.2025019468

Evaluating the Clinical Utility of Real-Time Comprehensive Whole Exome Sequencing and RNA-Seq for Patients with Diffuse Large B-Cell Lymphoma

Dai Chihara, Kumudha Balakrishnan, Gita Masand, R. Andrew Harkins, Neha Akkad et al. (24 authors)

Blood2024-11-05

10.1182/blood-2024-209105

Abstract PO-016: Test-the-test: Clinical utility of comprehensive whole exome sequencing (WES) and RNA-seq for lymphoma patients

Dai Chihara, Kumudha Balakrishnan, Gita Masand, Anna Novokreshchenova, Alexander Bagaev et al. (21 authors)

Blood Cancer Discovery2024-06-19

10.1158/2643-3249.lymphoma24-po-016

Abstract 1754: Test-the-test: Clinical utility of comprehensive whole exome sequencing (WES) and RNA-seq for lymphoma patients

Dai Chihara, Kumudha Balakrishnan, Gita Masand, Anna Novokreshchenova, Alexander Bagaev et al. (14 authors)

Cancer Research2024-03-22

10.1158/1538-7445.am2024-1754

Test-the-Test: Clinical Utility of Comprehensive Whole Exome Sequencing and RNA-Seq for Patients with Lymphoma

Dai Chihara, Kumudha Balakrishnan, Gita Masand, Anna Novokreshchenova, Alexander Bagaev et al. (14 authors)

Blood2023-11-021 citations

10.1182/blood-2023-189426

Interventions

OTHERMolecular Functional Portrait

Participants will be asked to allow previously-collected tumor tissue to be used for the MF Portrait test

Study design

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

OTHER

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

Patient Eligibility: Inclusion Criteria: 1. Male/female patients who are at least 18 years of age on the day of informed consent signing. 2. Patients must have a histologically documented diffuse large B-cell lymphoma requiring therapy. 3. Provision of written informed consent for the study.

Exclusion criteria

1\. None

Design outcomes

Primary

Measure	Time frame
Percentage of participants who have genomic test results available in <=7 days	through study completion an average of 1 year

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORJason Westin, MD

M.D. Anderson Cancer Center

Outcome results

None listed